Company Performance Metrics
- Michelle Khai: Chief Science/Scientist
- Shamila Hunter: Chief Executive Officer
Oxy Bump’s distinctive line of products are the only oxygen-infused nasal/throat sprays in mass market. They provide rapid relief without the side effects and contraindications associated with OTC medications.
The essential source of Oxy Bump’s globally acclaimed and clinically-verified benefits is oxygen itself. Each product is
formulated with a concentrate of oxygen in a safe and stable saline solution that is readily recognized and absorbed by the body, and delivers a potent boost of oxygen that improves overall health, as well as cleanses, moisturizes and reduces congestion.
As with all Oxy Bump products, they are pH neutral and non-addictive and can be used as much as needed without risk of overuse and have no adverse side-effects. It addresses an underserved market segment of today’s health-conscious consumers, who are increasingly demanding wellness products that are safe, family-friendly, and suitable for everyday use.
The oxygen-powered effectiveness of Oxy Bump is distinguished by an attention-grabbing bottle design, which was awarded with an NACD Gold design award. It creates colorful, eye-catching presentations that immediately capture shopper interest. Oxy Bump has a sharp contemporary design and vibrant color pops unique to the otherwise staid sinus/allergy category.
Having now reached the milestone of arriving on mass market retail shelves, capital is required to help accelerate the sell-through rates and establish the financial foundation from which the company will grow. High margins and primarily contract service from subject experts and professionals ensures access to the best possible skills but effectively manage overheads and allow Management to remain agile at this business stage. Minimal inventory lead time and minor capex requirements allows the Company to focus its resources on revenue generation and product line expansion. Break-even is expected in Q3 2016.
